Long-Term Assets: The sum of all assets classified as non-current.
Gyre Therapeutics, Inc. (GYRE) had Long-Term Assets of $61.34M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$22.06M |
|
$2.70M |
|
$0.89M |
|
$21.16M |
|
$19.79M |
|
$2.27M |
|
$2.36M |
|
$4.63M |
|
$4.63M |
|
$3.73M |
|
$3.73M |
|
$3.73M |
|
$3.73M |
|
$2.27M |
|
$2.81M |
|
86.42M |
|
101.97M |
|
$0.03 |
|
$0.00 |
|
| Balance Sheet Financials | |
$68.45M |
|
$23.52M |
|
|
Long-Term Assets |
$61.34M |
$129.79M |
|
$18.99M |
|
-- |
|
$6.50M |
|
$25.49M |
|
$104.30M |
|
$99.22M |
|
$104.30M |
|
87.64M |
|
| Cash Flow Statement Financials | |
$-0.13M |
|
$1.97M |
|
$1.34M |
|
$11.81M |
|
$15.04M |
|
$3.23M |
|
$0.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
95.95% |
|
10.30% |
|
10.30% |
|
-- |
|
21.01% |
|
12.23% |
|
$-0.25M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.11 |
|
1.08 |
|
83.15 |
|
3.58% |
|
3.76% |
|
2.88% |
|
3.58% |
|
$1.19 |
|
$-0.00 |
|
$-0.00 |
|